Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
22 studies found for:    pomalidomide | Open Studies | multiple myeloma | Phase 2
Show Display Options
Rank Status Study
1 Recruiting Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Multiple Myeloma, Refractory
Interventions: Drug: Pomalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
2 Recruiting Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Pegylated Liposomal Doxorubicin (PLD);   Drug: Dexamethasone
3 Recruiting Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bendamustine;   Drug: Pomalidomide;   Drug: Dexamethasone
4 Recruiting ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: ACY-1215 in combination with pomalidomide and dexamethasone
5 Recruiting A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Conditions: Multiple Myeloma;   First Relapse
Interventions: Drug: PCD;   Procedure: Autologous transplantation (ASCT)
6 Recruiting Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma Following Lenalidomide Plus Low Dose Dexamethasone as Second Line Treatment.
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Dexamethasone
7 Not yet recruiting Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: MK-3475;   Drug: Pomalidomide;   Drug: Dexamethasone
8 Recruiting Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Refractory Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Interventions: Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
9 Recruiting Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: carfilzomib;   Drug: dexamethasone
10 Recruiting A Study of Oprozomib, Pomalidomide, and Dexamethasone in Subjects With Primary Refractory or Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Oprozomib;   Drug: Pomalidomide;   Drug: Dexamethasone
11 Recruiting Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Romidepsin;   Drug: pomalidomide;   Drug: Dexamethasone
12 Recruiting A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Pomalidomide;   Drug: Dexamethasone
13 Recruiting Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Procedure: stem cell;   Drug: Dexamethasone;   Drug: Clarithromycin
14 Recruiting Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Condition: Refractory Multiple Myeloma
Interventions: Drug: ixazomib;   Drug: dexamethasone;   Drug: pomalidomide;   Other: laboratory biomarker analysis
15 Recruiting Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Pomalidomide;   Drug: Dexamethasone
16 Unknown  Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
Condition: Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: clarithromycin;   Drug: Pomalidomide
17 Not yet recruiting Pomalidomide for Lenalidomide for Failures
Condition: Multiple Myeloma
Interventions: Drug: POM;   Drug: Steroids;   Drug: PLD;   Drug: CFZ;   Drug: BTZ;   Drug: CLA;   Drug: Other drugs
18 Recruiting Pomalidomide and Dexamethasone With Growth Factor Support
Condition: Myeloma
Interventions: Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: G-CSF;   Behavioral: Phone Calls
19 Not yet recruiting Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib
Conditions: Multiple Myeloma;   Relapse After Use of Lenalidomide and Bortezomib
Intervention: Drug: Pomalidomide and Dexamethasone
20 Recruiting Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide
Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: Imnovid (pomalidomide);   Drug: Dexamethasone;   Drug: Endoxan (Cyclophosphamide)

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Indicates status has not been verified in more than two years